AnaptysBio, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 42.21 million compared to USD 26.41 million a year ago. Basic loss per share from continuing operations was USD 1.59 compared to USD 0.93 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21 USD | +11.29% | +5.69% | -1.96% |
Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.96% | 574M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023